Cocrystal Pharma (NASDAQ:COCP – Get Free Report) and Immuneering (NASDAQ:IMRX – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, profitability and risk.
Institutional and Insider Ownership
6.7% of Cocrystal Pharma shares are held by institutional investors. Comparatively, 67.7% of Immuneering shares are held by institutional investors. 39.4% of Cocrystal Pharma shares are held by insiders. Comparatively, 22.9% of Immuneering shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Risk & Volatility
Cocrystal Pharma has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500. Comparatively, Immuneering has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cocrystal Pharma | 1 | 0 | 0 | 0 | 1.00 |
| Immuneering | 1 | 0 | 4 | 1 | 2.83 |
Immuneering has a consensus price target of $16.50, indicating a potential upside of 274.15%. Given Immuneering’s stronger consensus rating and higher possible upside, analysts clearly believe Immuneering is more favorable than Cocrystal Pharma.
Earnings and Valuation
This table compares Cocrystal Pharma and Immuneering”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cocrystal Pharma | N/A | N/A | -$8.83 million | ($0.73) | -1.36 |
| Immuneering | N/A | N/A | -$56.03 million | ($1.17) | -3.77 |
Immuneering is trading at a lower price-to-earnings ratio than Cocrystal Pharma, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Cocrystal Pharma and Immuneering’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cocrystal Pharma | N/A | -150.61% | -97.86% |
| Immuneering | N/A | -31.93% | -29.92% |
Summary
Immuneering beats Cocrystal Pharma on 7 of the 12 factors compared between the two stocks.
About Cocrystal Pharma
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.
About Immuneering
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
